0001567619-20-014921.txt : 20200812
0001567619-20-014921.hdr.sgml : 20200812
20200812163259
ACCESSION NUMBER: 0001567619-20-014921
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200810
FILED AS OF DATE: 20200812
DATE AS OF CHANGE: 20200812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DEMANE MICHAEL F
CENTRAL INDEX KEY: 0001174533
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36715
FILM NUMBER: 201095855
MAIL ADDRESS:
STREET 1: MEDTRONIC INC
STREET 2: 710 MEDTRONIC PKWY, MS LC310
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55432-5604
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEVRO CORP
CENTRAL INDEX KEY: 0001444380
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 562568057
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 BRIDGE PARKWAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-251-0005
MAIL ADDRESS:
STREET 1: 1800 BRIDGE PARKWAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
4
1
doc1.xml
FORM 4
X0306
4
2020-08-10
0
0001444380
NEVRO CORP
NVRO
0001174533
DEMANE MICHAEL F
C/O NEVRO CORP.
1800 BRIDGE PARKWAY
REDWOOD CITY
CA
94065
1
0
0
0
Common Stock
2020-08-10
4
S
0
30469
134.3417
D
401039
D
Common Stock
2020-08-10
4
S
0
19785
135.5825
D
381254
D
Common Stock
2020-08-10
4
S
0
24208
136.1837
D
357046
D
Common Stock
2020-08-10
4
S
0
3813
138.4390
D
353233
D
Common Stock
2020-08-10
4
S
0
2337
138.8748
D
350896
D
Common Stock
2020-08-10
4
S
0
2828
140.11
D
348068
D
Common Stock
2020-08-10
4
S
0
1626
134.4178
D
40928
I
See footnote
Common Stock
2020-08-10
4
S
0
1474
135.6428
D
39454
I
See footnote
Common Stock
2020-08-10
4
S
0
1000
136.373
D
38454
I
See footnote
Common Stock
2020-08-10
4
S
0
400
138.6975
D
38054
I
See footnote
Common Stock
50000
I
See footnote
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $133.84 to $134.79, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Includes 1,376 restricted stock units.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $134.85 to $135.84, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $135.85 to $136.79, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $137.74 to $138.63, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $138.74 to $139.17, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $133.95 to $134.82, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Shares held by Catherine Q. DeMane Trustee, Michael F. DeMane 2012 Irrevocable Trust U/A/D July 26, 2012.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $134.96 to $135.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $135.96 to $136.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $138.57 to $139.06, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Shares held by Michael DeMane Trustee, Michael F. DeMane 2016 Retailed Annuity Trust U/A/D May 22, 2017.
/s/ Kashif Rashid, as Attorney-in-Fact for Michael DeMane
2020-08-12